Ones To Watch News
Refine Search
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Pharmaceutical
US clinical-stage drug developer Keros Therapeutics’ shares plummeted more than 73% to $18.20 in pre-market activity on revealing a setback for a lead investigational candidate. 12 December 2024
Biotechnology
California-based Day One Biopharmaceuticals has announced an exclusive licensing agreement with MabCare Therapeutics for MTX-13. 19 June 2024
Pharmaceutical
US chemoproteomics start-up Belharra Therapeutics, has entered into a strategic collaboration with French pharma major Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases. 19 June 2024
Biotechnology
Boston, USA-based biotech start-up Ascidian Therapeutics yesterday announced a research collaboration and licensing agreement with Roche for the discovery and development of RNA exon editing therapeutics targeting neurological diseases, adding to the Swiss pharma giant’s plethora of RNA alliances. 19 June 2024
Pharmaceutical
Marinus Pharmaceuticals has announced topline results showing partial success in the Phase III RAISE trial. 18 June 2024
Pharmaceutical
Shares of US drug developer Aerovate Therapeutics plummeted 93% yesterday and were down a further 6.7% at $1.54 pre-market, after it revealed it would scrap a late-stage development of its lead investigational candidate. 18 June 2024
Biotechnology
US liver disease focused biotech Mirum Pharmaceuticals (Nasdaq: MIRM) saw its shares leap 15.4% to $29.90 by close of trading on Monday, as it reported interim results from two Phase IIb studies evaluating volixibat. 18 June 2024
Biotechnology
Elion Therapeutics, a biotechnology company focusing on invasive fungal infections, has announced the successful closing of an $81 million series B funding round. 17 June 2024
Biotechnology
Multispecific ophthalmic specialist RevOpsis Therapeutics has announced a strategic manufacturing partnership with Kemwell Biopharma. 17 June 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Biotechnology
London, UK-based Syncona has announced that Freeline Therapeutics has acquired SwanBio Therapeutics to create a new company, Spur Therapeutics. 17 June 2024
Biotechnology
Ophthalmology specialist Ocular Therapeutix has highlighted impressive clinical development progress with Axpali (axitinib intravitreal implant) for wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR) at an investor day. 17 June 2024
Biotechnology
UK-based respiratory drug developer Enterprise Therapeutics has appointed Dr Renu Gupta as chief medical officer (CMO). 17 June 2024
Biotechnology
Australian clinical-stage ophthalmic specialist Opthea Limited says it has successfully completed an institutional component of the capital raising. 15 June 2024
Biotechnology
Avidity Biosciences, a biopharmaceutical company specializing in RNA therapeutics, has announced a public share offering, with the goal of raising $400 million. 14 June 2024
Biotechnology
China’s Innovent Biologics recently presented Phase I study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer. 14 June 2024
Pharmaceutical
Bladder cancer specialist UroGen Pharma saw its shares close up nearly 38% at $17.50 yesterday, after it shared positive trial results on its lead pipeline candidate UGN-102, an innovative formulation of mitomycin. 14 June 2024
Biosimilars
South Korea’s Samsung Bioepis today presented the post-hoc analysis of the Phase III clinical study results for Epysqli (SB12), a biosimilar to AstraZeneca’s Soliris (eculizumab), at the EHA Congress. 14 June 2024
Biotechnology
First launched in 2022, US precision immunology company Santa Ana Bio yesterday emerged from stealth with $168 million in combined Series A and B funding. 14 June 2024
Pharmaceutical
Alzheon, a clinical-stage biopharma company, has secured $100 million in a series E funding round led by Alerce Medical Technology Partners. 13 June 2024
Biotechnology
Oxford, UK-based start-up Ochre Bio has announced the start of a multi-year data licence agreement with British pharma major GSK. 13 June 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze